With mounting instances of genetic diseases, a demand for therapeutic measures has witnessed a hike, as no effective procedures exist that provide effective treatment of genetic or rare inflammatory diseases.
In a bid to curtail disease prevalence, several pharmaceutical industries have been making efforts to make advancements in relevant drugs and therapeutic methods.
For example, new treatment options are being developed by researchers for geriatric and pediatric patients suffering from Still’s disease, which is a rare disease linked with the inflammation of joints.
Doctors are stepping up their efforts by creating awareness among patients in regards to the benefits of anti-inflammatory drugs, which were deemed effective in the prevention and control of rare inflammatory diseases.
Currently, there is a rapid increase in the demand for authorised effective treatments of rare inflammatory diseases. The Office of Orphan Products Development (OOPD) has been offering incentives to drug companies, supporting the development of treatment methods for these diseases.
The National Institutes of Health (NIH) are providing immense support for improving patients’ health, by focusing mainly on the development of new treatment methods. Collaborative projects are being initiated by the NIH to examine the common causes and effects of related diseases.
Significant findings from the report show that the global market for rare inflammatory disease treatment will increase at an assessed 4.4% CAGR during the 2017-2026 forecast period. The report also anticipates that by the end of 2026, rare inflammatory disease treatments worth nearly $15.9m will be witnessed worldwide.
Increasing inflammatory and autoimmune diseases to create opportunities for new therapies
Several groups of scientists have associated cytokine IL-23 with the treatment of inflammatory and autoimmune diseases, which in turn is creating new ways of development for therapies.
Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organisational stimulation of receptor IL-23R.
The occurrence of inflammatory and autoimmune diseases is increasing at a rapid pace. Globally, an approximate number of 125 million people are affected by psoriasis and around 100 million by rheumatoid arthritis annually. The presence of inflammatory bowel infections such as ulcerative colitis and Crohn’s disease is also rapidly increasing in formerly unaffected fragments of the world.
The key takeaways from the rare inflammatory disease treatment market report for the 2017-2026 period include:
Key market players outlined by the report include Pfizer, Allergan, Valeant, Johnson & Johnson, Questcor Pharmaceuticals, Novartis, Abbvie, Abbott Laboratories, Regeneron Pharmaceuticals, and Swedish Orphan Biovitrum.
To request a sample report with a table of contents and figures, click here.
To preview analysis of the global rare inflammatory disease treatment market, segmented by indication type, drug class, mode of administration, and distribution channel, click here.
FMI’s advisory services aim to help you with specific, customised insights that are relevant to your specific challenges. Contact the company today using the form on this page to discuss your challenges with its trusted advisors.